Clinical trial
Standard vs. Biofilm Susceptibility Testing in Cystic Fibrosis (CF)
NCT00153634 · Seattle Children's Hospital, Other · Completed
Key facts
| NCT number | NCT00153634 |
|---|---|
| Title | Standard vs. Biofilm Susceptibility Testing in Cystic Fibrosis (CF) |
| Official title | Standard vs. Biofilm Susceptibility Testing in CF |
| Lead sponsor | Seattle Children's Hospital, Other |
| Collaborators | Cystic Fibrosis Foundation |
| Status | Completed |
| Study type | Interventional |
| Conditions | Cystic Fibrosis, Chronic Bronchitis |
| Intervention type | Drug |
| Interventions | IV amikacin, PO azithromycin, IV ceftazidime, PO ciprofloxacin, IV meropenem, IV piperacillin-tazobactam, IV ticarcillin-clavulanate, IV tobramycin |
| Enrollment | 75 |
| Start date | Mar 1, 2004 |
| Completion | Nov 1, 2007 |
| First posted | Sep 12, 2005 |
| Last update posted | Mar 13, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: